Catalyst
Slingshot members are tracking this event:
Initiation of two Phase 3 trials for Fitusiran (ALN-AT3), in treating severe hemophilia A and B patients with and without inhibitors is expected in early 2017
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| ALNY | Community voting in process | |||||
Additional Information
Slingshot Insights Explained
Catalyst Date
Occurred on:
Sep 07, 2017
Occurred Source:
http://investors.alnylam.com/releasedetail.cfm?ReleaseID=1039464
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Phase 3 Trials, Fitusiran, Aln-at3, Severe Hemophilia A, Hemophilia B
